BIORCHESTRA

What BIORCHESTRA does

BIORCHESTRA Co., Ltd. is a South Korea-based private biotechnology company founded in 2016 by Dr. Branden Ryu, headquartered in Daejeon with a U.S. subsidiary in Cambridge, Massachusetts. The company develops IV-formulated RNA-based therapeutics targeting neurodegenerative and rare central nervous system diseases, including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and epilepsy. Its core technology is the proprietary BDDS™ (Brain Targeting Drug Delivery System), a non-lipid nanoparticle platform that crosses the blood-brain barrier via LAT1 transporter-mediated transcytosis to deliver ASO, SSO, siRNA, mRNA, peptide, and small protein cargos to neurons, astrocytes, and microglia. The lead clinical-stage candidate, BMD-001, is an antisense oligonucleotide targeting miR-485-3p, a microRNA identified by BIORCHESTRA as the first linked to degenerative brain diseases, with demonstrated 64-fold higher brain tissue delivery versus naked ASO and efficacy in non-human primate models.

The company's pipeline includes BMD-002 (epilepsy ASO under SK Biopharmaceuticals co-development), BMD-003 (metabolic disease LNA-Gapmer), and BIOK-001 (neuroinflammatory). Business operations are built around a partnership-led go-to-market model: BIORCHESTRA monetizes its platform through strategic licensing and co-development agreements with global pharmaceutical companies, headlined by a March 2023 exclusive research, option, and licensing agreement worth up to $861 million with an unnamed global biopharmaceutical company for the CNS-targeted polymeric nanoparticle platform. The company is pre-revenue, generating no product sales, with future revenue expected from upfront payments, development and commercial milestones, and royalties on partnered programs. It operates GMP manufacturing in Daejeon, has raised approximately $60M+ in equity capital through Series A/B/C rounds from a mix of Korean financial and strategic investors (IMM Investment, SBI Investment, GS Holdings, Chong Kun Dang), and has won awards including the J&J Innovation QuickFire Challenge (2021) and the Merck Advance Biotech Grand Prize (2023).

Name

BIORCHESTRA

Legal name

BIORCHESTRA Co., Ltd.

Website

https://biorchestra.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

BIORCHESTRA is a South Korean clinical-stage biotech developing IV-formulated RNA therapeutics delivered via its proprietary BDDS™ brain-targeting nanoparticle platform to treat neurodegenerative and rare CNS diseases, monetized through licensing and co-development partnerships with global pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), siRNA Therapeutics (gene silencing) (HLAAADAB), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)

Keywords

• RNA therapeutics
• Brain drug delivery
• Neurodegenerative disease treatment
• Antisense oligonucleotide therapeutics
• Blood-brain barrier platform

Headquarters

HQ city

Yusong

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Licensing and Partnership Revenue: Pre-revenue biotech company focused on developing RNA therapeutics. Generating revenue through strategic licensing agreements and co-development partnerships with global pharmaceutical companies. The $861M deal with a global biopharma company represents potential milestone and royalty payments.
2. Future Product Sales: Post-approval, the company plans to commercialize its pipeline of RNA therapeutics for neurodegenerative diseases. Lead program BMD-001 targets Alzheimer's, ALS, and Parkinson's disease.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

BIORCHESTRA develops IV-formulated RNA-based therapeutics using its proprietary BDDS™ (Brain Targeting Drug Delivery System) platform—a non-lipid nanoparticle carrier that delivers antisense oligonucleotides (ASOs), siRNAs, and mRNAs across the blood-brain barrier via LAT1 transporter targeting. The company advances a pipeline of drug candidates (BMD-001, BMD-002, BMD-003, BIOK-001) targeting neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, epilepsy, metabolic disease, and neuroinflammation, while licensing its delivery platform to global pharmaceutical partners.

Product overview

BIORCHESTRA is a biotherapeutics company developing transformational RNA medicines and delivery systems for neurodegenerative and rare diseases of the Central Nervous System. The company's core offering is the BDDS™ (Brain Targeting Drug Delivery System) platform—a proprietary non-lipid nanoparticle technology that enables IV administration of various RNA cargos (ASO, siRNA, mRNA) to cross the blood-brain barrier and reach brain cells. The platform is utilized across their pipeline: lead program BMD-001 is an IV-formulated ASO targeting miR-485-3p for Alzheimer's, ALS, and Parkinson's disease; BMD-002 targets epilepsy; BMD-003 addresses metabolic disease; and BIOK-001 focuses on neuroinflammatory conditions. The company also operates GMP manufacturing facilities in Daejeon, Korea and has U.S. headquarters in Cambridge, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

• BDDS™ Platform (Brain Targeting Drug Delivery System) A proprietary non-lipid nanoparticle carrier platform designed to efficiently deliver active pharmaceutical ingredients (ASO, SSO, siRNA, mRNA, peptides, small proteins) to all regions of the CNS via IV administration. Features ligand amendment for preferential organ/tissue distribution, longer-term stability in circulation, and a favorable safety profile. The platform is licensed to global biopharmaceutical companies for CNS drug development.
• BMD-001 Lead IV-formulated nanomedicine drug candidate targeting miR-485-3p, a microRNA implicated in Alzheimer's disease, ALS, and Parkinson's disease. Demonstrates amyloid-β clearance, tau protein deposition reduction, neuroinflammation decrease, and cognitive function improvement in non-human primate models. Uses BDDS™ delivery platform.
• BMD-002 BDDS-encapsulated antisense oligonucleotide (ASO) drug candidate targeting epilepsy. Developed under co-development partnership with SK Biopharmaceuticals; targets miRNA for new epilepsy therapeutics.
• BMD-003 LNA-Gapmer drug candidate program for metabolic disease using locked nucleic acid technology. Development stage undisclosed.
• BIOK-001 BDDS-delivered drug candidate program targeting neuroinflammatory disease. Development stage undisclosed.

Quantifiable outcome

• 64-fold higher brain tissue delivery ratio compared to ASOs without NP carrier (Phe-NPs/ASO)
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Global Biopharmaceutical CompanycoreStrategic or Co-development Partner · 27 March 2023Exclusive research, option, and licensing agreement worth up to $861M for CNS-targeted polymeric nanoparticle platform. Collaboration on initial target with option for additional targets. Global partner leveraging BDDS technology for nucleic acid therapy development.
• Merck GroupminorOthers · 1 January 2023Merck Advance Biotech Grant Program winner. BIORCHESTRA received in-kind products and services from Merck to support CNS RNA therapeutic development.
• SK BiopharmaceuticalscoreStrategic or Co-development Partner · 5 January 2022Partnership to research and develop miRNA-targeted therapeutics for epilepsy. BIORCHESTRA provides target discovery, selection, synthesis, and ASO platform with BDDS delivery. Joint IP ownership with SK Biopharmaceuticals handling preclinical studies and expansion to other CNS indications.
• Korea Research Institute of Bioscience and Biotechnology (KRIBB)minorStrategic or Co-development PartnerResearch collaboration with National Primate Research Center for non-human primate studies of BMD-001

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases with a proprietary BBB delivery platform (ATV enabled by TfR targeting). Highly comparable to BIORCHESTRA's BDDS platform approach, both companies focus on solving BBB penetration for CNS targets including Alzheimer's and Parkinson's disease.
• Wave Life Sciences: Wave Life Sciences develops stereopure antisense oligonucleotides targeting CNS diseases including Huntington's disease, ALS, and frontotemporal dementia. Comparable as a direct competitor in RNA-based therapeutics for neurodegenerative indications using proprietary chemistry platforms.
• PepGen: PepGen develops cell-penetrating peptide-conjugated oligonucleotides for Duchenne muscular dystrophy and DM1, with peptide-based delivery analogous to BIORCHESTRA's polymer nanoparticle approach for CNS delivery of RNA therapeutics.
• Atalanta Therapeutics: Atalanta Therapeutics is developing siRNA therapeutics for neurodegenerative diseases including ALS, Huntington's, and Parkinson's, with branched siRNA technology to achieve broad brain biodistribution. Direct competitor in CNS-targeted RNA therapeutics addressing similar indications as BIORCHESTRA's BMD-001.
• Stoke Therapeutics: Stoke Therapeutics develops antisense oligonucleotides using its TANGO platform for CNS diseases including Dravet syndrome and autosomal dominant optic atrophy. Similar business model of platform-based ASO development targeting rare and severe neurological diseases via RNA-based mechanisms.
• Voyager Therapeutics: Voyager Therapeutics develops gene therapies and RNA-based therapeutics for CNS diseases including Parkinson's, Huntington's, and ALS. Comparable as a CNS-focused biotech with proprietary delivery technology (TRACER capsids) targeting the brain, similar to BIORCHESTRA's BDDS platform approach.

Broad incumbents

• Ionis Pharmaceuticals: Ionis is the pioneer and leader in antisense oligonucleotide therapeutics with multiple approved ASO drugs (Spinraza, Tegsedi, Waylivra) and a deep CNS pipeline. BIORCHESTRA's CMO Dr. O'Dea is former CMO of Ionis subsidiary Akcea, highlighting the operational and competitive adjacency.
• Alnylam Pharmaceuticals: Alnylam is the global leader in siRNA therapeutics with multiple approved drugs and a CNS program (with Regeneron) for Huntingtin's, C9orf72, and SOD1. Comparable as an RNA therapeutics leader with active CNS pipeline and significant delivery technology investment.
• Moderna: Moderna is the leading mRNA therapeutics company, founded by Dr. O'Dea (now BIORCHESTRA's President/CMO). Comparable as an mRNA delivery and therapeutic development leader, though operating at vastly greater scale with an approved vaccine and broad pipeline.

Others

• Acuitas Therapeutics: Acuitas Therapeutics is a leading lipid nanoparticle (LNP) delivery technology provider whose LNP technology underpins Moderna's COVID-19 vaccine and Pfizer/BioNTech's Comirnaty. Comparable as a nucleic acid delivery specialist enabling partners' RNA therapeutic development, though focused on LNP versus BIORCHESTRA's polymer nanoparticle approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BIORCHESTRA_
• LinkedInlinkedin.com/company/biorchestra-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIORCHESTRA